VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).
The DOI matches its Crossref record.
Abstract
3518^ Background: Low prevalence of V600m in non-melanoma cancers requires novel trial designs to assess the activity of BRAF inhibitors. Based on preclinical models that V600m positive (+) CRC upregulates the EGFR pathway and sensitizes to EGFR inhibitors in response to VEM (Prahallad et al Nature 2012), we investigated the activity of VEM in V600m+ CRC with or without CTX. Here we present preliminary efficacy and safety data for the VEM cohort and VEM + CTX dose-finding cohorts. Methods: This multicohort, Simon 2-stage adaptive design, single-proportion study included adult patients (pts) with V600m+ cancers refractory to standard therapy or for whom standard/curative therapy is not available. Pretreated CRC pts received either VEM (960 mg bid) without (cohort 3a) or with CTX (cohort 3b, 3+3 dose escalation) until investigator (INV)-assessed disease progression or unacceptable toxicity. Primary objective was INV-assessed response rate at wk 8 (RECIST v1.1). Maximum tolerated dose (MTD) and recommended dose (RD) were to be determined for the VEM + CTX cohort. Results: Median (range) treatment duration was: cohort 3a, 77 (24-225) d; 3b, 114 (36-279) d. At stage I, no responses were observed in cohort 3a (n=10). In cohort 3b, 14 pts have been enrolled for determination of MTD/RD. No dose-limiting toxicities (DLT) have been observed in dose level (DL) 1 (VEM 720 mg bid/CTX 200 mg/m2/wk) and DL 2 (VEM 720 mg bid/CTX 250 mg/m2/wk); 1 pt experienced a DLT (asymptomatic amylase grade 3 and lipase grade 4 elevation) in DL 3 (VEM 960 mg bid/CTX 250 mg/m2/wk). Preliminary response data are in table. DL 3 was selected as the RD. There were no unexpected safety findings in either cohort. Conclusions: VEM + CTX show early signs of activity in V600m+ CRC; a formal evaluation of efficacy and safety results will be provided at the meeting. VEM monotherapy is not effective in V600m+ CRC. Clinical trial information: NCT01524978. n Week 8 Week 16 Week 24 DL 1 DL2 DL 3 DL 1 DL 2 DL 3 DL 1 DL 2 Pts with tumor assessment 3 2 5 3 1 3 2 1 Complete response 0 0 0 0 0 0 0 0 Partial response 1 1 0 1 0 0 1 0 Stable disease 2 1 3 1 1 2 1 1 Progressive disease 0 0 2 1 0 1 0 0 Clinical benefit 3 2 3 2 1 2 2 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507
Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486
Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1518 · Cited by 322
Yaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2779 · Cited by 276
Oddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0396 · Cited by 121
Self-citation
Metadata
- Authors
- Tabernero, J., Chan, E., Baselga, J., Blay, J.-Y., Chau, I., Hyman, D. M., Raje, N. S., Wolf, J., Sirzen, F., Veronese, M. L., Mitchell, L., & Hidalgo, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-05-20
- Volume
- 32
- Issue
- 15_suppl
- Pages
- 3518-3518
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2600831328
- Cited by
- 32
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.3518
- The paper
- Tabernero, J., Chan, E., Baselga, J., Blay, J.-Y., Chau, I., Hyman, D. M., Raje, N. S., Wolf, J., Sirzen, F., Veronese, M. L., Mitchell, L., & Hidalgo, M. (2014). VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.3518
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.